Company Quick10K Filing
Vertex Pharmaceuticals
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 260 $46,842
10-Q 2019-10-31 Quarter: 2019-09-30
10-Q 2019-08-01 Quarter: 2019-06-30
10-Q 2019-05-01 Quarter: 2019-03-31
10-K 2019-02-13 Annual: 2018-12-31
10-Q 2018-10-25 Quarter: 2018-09-30
10-Q 2018-07-26 Quarter: 2018-06-30
10-Q 2018-04-27 Quarter: 2018-03-31
10-K 2018-02-15 Annual: 2017-12-31
10-Q 2017-10-30 Quarter: 2017-09-30
10-Q 2017-07-28 Quarter: 2017-06-30
10-Q 2017-04-28 Quarter: 2017-03-31
10-K 2017-02-23 Annual: 2016-12-31
10-Q 2016-10-31 Quarter: 2016-09-30
10-Q 2016-08-01 Quarter: 2016-06-30
10-Q 2016-05-03 Quarter: 2016-03-31
10-K 2016-02-16 Annual: 2015-12-31
10-Q 2015-10-30 Quarter: 2015-09-30
10-Q 2015-08-04 Quarter: 2015-06-30
10-Q 2015-05-04 Quarter: 2015-03-31
10-K 2015-02-13 Annual: 2014-12-31
10-Q 2014-11-06 Quarter: 2014-09-30
10-Q 2014-07-31 Quarter: 2014-06-30
10-Q 2014-05-05 Quarter: 2014-03-31
10-K 2014-02-11 Annual: 2013-12-31
10-Q 2013-11-07 Quarter: 2013-09-30
10-Q 2013-08-02 Quarter: 2013-06-30
10-Q 2013-05-08 Quarter: 2013-03-31
10-K 2013-03-01 Annual: 2012-12-31
10-Q 2012-11-06 Quarter: 2012-09-30
10-Q 2012-08-08 Quarter: 2012-06-30
10-Q 2012-05-10 Quarter: 2012-03-31
10-K 2012-02-22 Annual: 2011-12-31
10-Q 2011-11-03 Quarter: 2011-09-30
10-Q 2011-08-09 Quarter: 2011-06-30
10-Q 2011-05-06 Quarter: 2011-03-31
10-Q 2010-10-28 Quarter: 2010-09-30
10-Q 2010-08-03 Quarter: 2010-06-30
10-Q 2010-05-03 Quarter: 2010-03-31
10-K 2010-02-19 Annual: 2009-12-31
8-K 2019-10-30 Earnings, Exhibits
8-K 2019-10-24 Other Events
8-K 2019-09-17 Enter Agreement, Leave Agreement, Off-BS Arrangement, Off-BS Arrangement
8-K 2019-08-30 Enter Agreement
8-K 2019-07-31 Earnings, Exhibits
8-K 2019-07-24 Officers, Exhibits
8-K 2019-06-06 Enter Agreement
8-K 2019-06-05 Officers, Shareholder Vote
8-K 2019-04-30 Earnings, Exhibits
8-K 2019-03-28 Officers
8-K 2019-02-21 Officers
8-K 2019-02-05 Earnings, Exhibits
8-K 2019-01-23 Officers
8-K 2018-12-13 Officers
8-K 2018-10-24 Earnings, Exhibits
8-K 2018-07-25 Earnings, Exhibits
8-K 2018-05-17 Enter Agreement, Shareholder Vote
8-K 2018-04-26 Earnings, Exhibits
8-K 2018-02-12 Regulation FD
8-K 2018-01-31 Earnings, Exhibits

Vertex Pharmaceuticals Financials

VRTX Metrics, Comps, Filings

Annual | Quarterly

Business

We invest in scientific innovation to create transformative medicines for people with serious diseases. Our business is focused on developing and commercializing therapies for the treatment of cystic fibrosis, or CF, and advancing our research and development programs in other diseases.

Our goal is to develop treatment regimens that will provide benefits to all patients with CF and will enhance the benefits that currently are being provided to patients taking our medicines. Our marketed medicines are SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor). These three medicines are collectively approved to treat approximately half of the 75,000 CF patients in North America, Europe and Australia.

We believe the triple combination regimens of next-generation correctors in combination with tezacaftor and ivacaftor that we are evaluating in Phase 3 clinical development could potentially provide benefits to all CF patients who have at least one F508del mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene (approximately 90% of all CF patients). This would provide (i) the first treatment for the underlying cause of CF for patients who have one copy of the F508del mutation in their CFTR gene and a second mutation that results in minimal CFTR function, whom we refer to as F508del/Min patients; and (ii) an improved treatment option for a majority of patients who are currently eligible for our products.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Bristol Myers Squibb (BMY) 73,829 53% 8.4 11% 55,163 39,012 23,857 12,640 6,226 8,365 69,858
Celgene (CELG) 67,154 96% 10.4 13% 39,183 29,132 16,354 15,736 5,271 7,702 79,730
GW Pharmaceuticals (GWPH) 64,239 88% -1,554.6 -6% 843 114 114 100 -50 -41 63,656
Allergan (AGN) 54,767 85% 80.8 -4% 123,846 38,273 15,678 13,341 -5,356 939 75,841
Zoetis (ZTS) 54,569 67% 25.9 13% 10,986 8,575 6,046 4,046 1,375 2,291 59,314
Sanofi (SNY) 52,845 0% 111,408 0 0 0 0 52,184
Vertex Pharmaceuticals (VRTX) 46,842 87% 16.9 33% 7,033 1,964 3,454 2,990 2,355 2,569 43,540
Regeneron Pharmaceuticals (REGN) 35,984 0% 15.2 16% 13,174 3,418 7,237 0 2,069 2,295 34,925
Alexion Pharmaceuticals (ALXN) 28,246 71% 15.7 9% 14,568 4,404 4,499 3,191 1,334 1,835 28,827
Biomarin Pharmaceutical (BMRN) 15,774 79% 680.7 -3% 4,393 1,432 1,533 1,213 -110 24 16,336
Elanco Animal Health (ELAN) 12,085 52% 30.6 2% 8,857 3,591 3,073 1,591 144 460 14,098
Mylan (MYL) 9,779 34% 8.3 0% 31,817 19,914 11,245 3,793 34 2,748 22,896
Teva (TEVA) 9,708 44% -13.7 -6% 59,424 44,173 17,720 7,741 -3,851 -2,437 33,498
Sarepta Therapeutics (SRPT) 9,465 0% -16.1 -33% 1,748 649 345 0 -570 -518 8,352
Ionis Pharmaceuticals (IONS) 9,097 57% 30.7 17% 2,878 1,421 799 459 495 287 8,825
Sage Therapeutics (SAGE) 8,814 51% -14.1 -47% 1,316 113 2 1 -613 -612 8,646
Bausch (BHC) 8,750 0% 25.1 -3% 32,354 29,666 8,425 0 -911 1,285 32,239
Alnylam Pharmaceuticals (ALNY) 7,978 91% -8.0 -32% 2,716 959 101 92 -858 -856 6,838
Catalent (CTLT) 7,731 32% 25.4 2% 6,184 3,896 2,518 805 137 408 10,377
Jazz Pharmaceuticals (JAZZ) 7,584 22% 10.2 12% 5,489 2,505 2,027 441 656 858 8,730

Balance Sheet ($MM)2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash2434754895696257151,1841,6652,658
Accounts Receivable131831438676178201281410
Inventory1123014315778112124
PP&E151334341,005716698698789812
Assets1,7252,2042,7592,3192,3352,4992,8973,5466,246
Accounts Payable36751014971756174111
Long-Term Debt
Liabilities1,2211,2391,5259631,2381,4051,5591,5041,811
Stockholders' Equity7879991,3561,0759401,1572,0294,435
Income Statement ($MM)2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue1439511,3338384881,0001,6842,1653,048
Cost of Revenue410
Gross Profit2,638
R&D6377088069198569961,0481,3251,416
SG&A188401437362305377433496558
Tax01939-28912-3-107-1,487
Net Income-75541-51-688-743-588-84922,087
Cash Flow ($MM)2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating-635144268-52-513-3652368451,270
Cash Investing7212-426-5474269104-438-202
Cash Financing425-12417218149718913368-71